GlassScriptPhysician profile
Gregory L Curry
NPI 1750377719
$3,741.47
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $98.04 · 2021: $790 · 2022: $1,126 · 2023: $943 · 2024: $16.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.16 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $574.70 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $546.07 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $419.55 | 2019-2023 | Prolia, Evenity |
| Abbott Laboratories | $247.06 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.15 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.43 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $66.74 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $60.54 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $59.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $35.81 | 2021-2023 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $35.65 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.16 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $28.79 | 2021 | Tlando, Xyosted |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.72 | 2019-2023 | |
| Biogen, INC. | $20.73 | 2022 | |
| Mannkind Corporation | $20.33 | 2020 | |
| Organogenesis INC. | $19.76 | 2021 | |
| Halozyme INC | $17.74 | 2023 | |
| Antares Pharma, INC. | $17.53 | 2023 | Xyosted, Tlando, Nocdurna |
| Bausch Health US, LLC | $17.23 | 2019 | |
| Amarin Pharma, INC. | $16.08 | 2021 | |
| Cequr Corporation | $15.79 | 2023 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $15.61 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.58 | 2021 | |
| Hologic Sales and Service, LLC | $15.51 | 2019 | |
| Merck Sharp & Dohme LLC | $14.44 | 2019 | |
| Eisai INC. | $14.31 | 2021 | |
| Horizon Therapeutics Plc | $14.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.62 | 2019 | |
| Boston Scientific Corporation | $13.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.15 | 2019 | |
| Shire North American Group INC | $12.04 | 2019 | |
| Sanofi Pasteur INC. | $11.95 | 2019 | |
| Exeltis, USA INC. | $11.92 | 2022 | |
| Endo Pharmaceuticals INC. | $11.75 | 2021 | |
| Adlon Therapeutics L.P. | $11.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.